Under an agreement
with a leading European sensor developer, Zenosense is developing a device
intended for the detection of the Methicillin-resistant Staphylococcus aureus
(MRSA) “Super-Bug”, commonly known as the staph infection. Zenosense has
exclusive global licensing rights for the sensory device, which is being
designed for use in hospitals and other healthcare settings.
Under its
development and exclusive global licensing agreement, Zenosense also has rights
to development and marketing of sensory devices that can detect certain types
of cancer within their early stages. The company notes that there is a strong
need for an early-stage cancer detection device. It believes that the sensory
technology and algorithmic processing it is currently developing could be
adapted for early detection of cancers such as lung cancer and colon cancer.
At present, lung
cancer is typically identified at a stage of development in which fewer than 25
percent of cases are curable. However, when it is detected at stage-one, there
is a cure rate of over 70 percent. The development of a device with these
capabilities would have tremendous implications for improved patient survival
rates of lung and colon cancer, and subsequently substantial impacts on the
healthcare delivery costs usually associated with cancer healthcare
service-providing.
Currently,
Zenosense’s sensor developer partner, the Sgenia Group, is working on
pioneering rapid, low-cost detection measures for the staph infection.
Zenosense intends to deploy this potentially cutting-edge sensory technology to
healthcare settings for alleviating healthcare-associated infections and their
heavy-handed influence on medical service costs. In the United States alone, it
is estimated that between $3.2 billion and $4.2 billion is spent per year on
treatment of hospitalized staph-infected patients. Patients who have contracted
MRSA are reported to be likely to spend three times as long in a hospital stay
at three times the cost, and are five times more likely to die than an
uninfected patient.
Utilizing
specialized hardware and state-of-the-art “sniffer” technology, the medical
device is expected to function as a medical “smoke detector” and identify any
presence of MRSA in a healthcare setting or infected patient before the
presence of MRSA is more noticeable. With its electronic nose, the device would
have the technological potency of tens of thousands of “virtual sensors”
wrapped into a single, high-performance sensory capability.
Once it is finally
developed, the detection device will be capable of being worn by patients as
well as deployed to critical locations within hospital settings. Recent studies
confirm the tremendous potential for Zenosense’s medical device: implementation
of such preventative practices could reduce certain HAIs by up to 70 percent.
For more information
about Zenosense, please visit: www.zenosense.net
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment